LDL-C THERAPEUTIC TARGET ATTAINMENT IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE

被引：0
|
作者：
Underberg, James [1 ]
Harada-Shiba, Mariko [2 ]
Hegele, Robert A. [3 ]
McCullough, Peter A. [4 ]
DiGioia, Kenneth [5 ]
Jurecka, Agnieszka [5 ]
Stefanutti, Claudia [6 ]
Blom, Dirk [7 ]
机构：
[1] NYU, Ctr Prevent Cardiovasc Dis, New York, NY USA
[2] Natl Cerebral & Cardiovasc Ctr, Res Inst, Osaka, Japan
[3] Robarts Res Inst, London, ON, Canada
[4] Baylor Univ, Med Ctr, Dallas, TX USA
[5] Aeger Pharmaceut, Cambridge, MA USA
[6] Sapienza Univ Rome, Rome, Italy
[7] Univ Cape Town, Cape Town, South Africa
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷
关键词：
D O I：
10.1016/j.atherosclerosissup.2018.04.468
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
P5.046
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [21] US FDA approves lomitapide for homozygous familial hypercholesterolemia
    Wilson, Hannah
    CLINICAL LIPIDOLOGY, 2013, 8 (01) : 11 - 12
  • [22] Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study
    Cuchel, Marina
    Blom, Dirk J.
    Averna, Maurizio R.
    Meagher, Emma A.
    Theron, Hendrik D.
    Sirtori, Cesare R.
    Hegele, Robert A.
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    Bloedon, LeAnne T.
    Rader, Daniel J.
    CIRCULATION, 2013, 128 (22)
  • [23] Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia
    Davis, Kyle A.
    Miyares, Marta A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (12) : 1001 - 1008
  • [24] Lomitapide in homozygous familial hypercholesterolemia: our clinical experience
    Citta, D.
    Nota, F.
    Napoli, F.
    Frascaroli, C.
    Pisu, E.
    Massucco, P.
    Cavalot, F.
    Bonomo, K.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 131 - 131
  • [25] EFFICACY OF LOMITAPIDE ACROSS THE SPECTRUM OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Hegele, Robert A.
    Shah, Prediman K.
    DiGioia, Kenneth
    Jurecka, Agnieszka
    Blom, Dirk
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 149 - 149
  • [26] New insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience
    Iannuzzo, Gabriella
    Calcaterra, Ilenia Lorenza
    Gentile, Marco
    Stanzione, Claudia
    de Ruberto, Francesca
    di Taranto, Maria Donata
    Cardiero, Giovanna
    Fortunato, Giuliana
    Di Minno, Matteo
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [27] The LDL Receptor Genotype Among Patients With Homozygous Familial Hypercholesterolemia is a Significant Determinant of the Rebound Increase in LDL-C Concentrations Following Lipoprotein Apheresis
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Lamarche, Benoit
    Couture, Patrick
    CIRCULATION, 2016, 134
  • [28] Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia
    Caroline M. Perry
    American Journal of Cardiovascular Drugs, 2013, 13 : 285 - 296
  • [29] LDL-C GENETIC RISK SCORES IN FAMILIAL HYPERCHOLESTEROLEMIA PHENOTYPE
    Medeiros, Ana M.
    Alves, Ana C.
    Bourbon, Mafalda
    MEDICINE, 2023, 102 (13)
  • [30] LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C
    van Delden, Xander M.
    Huijgen, Roeland
    Wolmarans, Karen H.
    Brice, Brigitte C.
    Barron, Jennifer K.
    Blom, Dirk J.
    Marais, A. David
    ATHEROSCLEROSIS, 2018, 277 : 327 - 333
12345